Skip to content

Alkermes ALKS Gross Profit

Gross Profit at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.07B-1.2%
AbbVie logo
AbbVieABBV
$10.78B+15.4%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Calculated from Alkermes’s reported figures.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's gross profit?
Alkermes (ALKS) reported gross profit of $331.33M in Q1 2026.
How has Alkermes's gross profit changed year-over-year?
Alkermes's gross profit increased by 28.8% year-over-year, from $257.31M to $331.33M.
What is the long-term trend for Alkermes's gross profit?
Over 4 years (2021 to 2025), Alkermes's gross profit has grown at a 7.0% compound annual growth rate (CAGR), from $976.43M to $1.28B.